Belatacept in renal transplantation in comparison to tacrolimus and molecular understanding of resistance pattern: Meta-analysis and systematic review

Figure 4 Forest plot represents the changes at 12 mo in kidney transplant recipients when treated with belatacept or tacrolimus. Squares represent size effects of studies, comparing the weight of the study in the meta-analysis. 95 percent confidence intervals represented in horizontal bars. A: The eGFR at 12 mo in kidney transplant recipients; B: The biopsy proven acute rejection over 12 mo in kidney transplant recipients. The diamond shows significant favour towards tacrolimus group following random effect analysis; C: Graft survival over 12 mo in kidney transplant recipients. The diamond shows significant favour towards tacrolimus group following fixed effect analysis; D: The adverse events over 12 mo in kidney transplant recipients. The diamond doesn't suggest any significant difference following fixed effects analysis; E: The BK virus infection over 12 mo in kidney transplant recipients. The diamond doesn't suggest any significant difference following fixed effects analysis; F: The new onset diabetes mellitus after transplantation over 12 mo in kidney transplant recipients. The diamond suggests significant favour towards belatacept group following fixed effects analysis.